Similarly, drugs like oxcarbazepine, traditionally used to treat epilepsy, have shown promise in managing movement disorders associated with GNAO1 mutations, further emphasizing the utility of C. elegans in pre-clinical drug screening (Ling et al., 2022). The gene discussed is GNAO1; the disease is movement disorder.